Brendan Hannah has served as Quince Therapeutics’ Chief Business Officer since May 2022. To this role, he brings 14 years of corporate development, operational, finance, and company formation experience. Previously, Mr. Hannah was Chief Operating Officer at Novosteo where he led the company’s operational and finance activities, including business development, commercial strategy, financial planning and analysis, and investor relations. Previously, he was Chief Business Officer at Neuroptika where he led business operations and global R&D for a nerve regenerative therapeutic spanning advancement from preclinical studies through Phase 2 study. Prior to that, Mr. Hannah was Head of Corporate Development at Agenovir, a CRISPR/Cas company focused on eliminating viral reservoirs where he led the acquisition of Agenovir by Vir Bio for up to $290 million. Previously, he was Director of Business Development at Cidara Therapeutics (CDTX). He started his career in business development at Trius Therapeutics (TSRX) where he had increasing roles of responsibility, culminating in his group leading an acquisition by Cubist Pharmaceuticals valued at more than $700 million upfront. Mr. Hannah received a M.B.A. with honors from University of California, Los Angeles, Anderson School of Management and received a B.A. in Economics from Colorado College.